Sernova Corp. (SEOVF)
USD 0.15
(0.34%)
USD 0.15
(0.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 40.68 Million CAD | 64.36% |
| 2022 | 24.75 Million CAD | 256.86% |
| 2021 | 6.93 Million CAD | 31.88% |
| 2020 | 5.25 Million CAD | 31.23% |
| 2019 | 4 Million CAD | 8.14% |
| 2018 | 3.7 Million CAD | 40.21% |
| 2017 | 2.64 Million CAD | 5.67% |
| 2016 | 2.5 Million CAD | -13.31% |
| 2015 | 2.88 Million CAD | 3.3% |
| 2014 | 2.79 Million CAD | 35.27% |
| 2013 | 2.06 Million CAD | -20.67% |
| 2012 | 2.6 Million CAD | 12.17% |
| 2011 | 2.32 Million CAD | 25.82% |
| 2010 | 1.84 Million CAD | 24.09% |
| 2009 | 1.48 Million CAD | -47.54% |
| 2008 | 2.83 Million CAD | -23.77% |
| 2007 | 3.71 Million CAD | 178.25% |
| 2006 | 1.33 Million CAD | 210.01% |
| 2005 | 430.94 Thousand CAD | -34.46% |
| 2004 | 657.48 Thousand CAD | -21.97% |
| 2003 | 842.59 Thousand CAD | -44.31% |
| 2002 | 1.51 Million CAD | -31.88% |
| 2001 | 2.22 Million CAD | 367.82% |
| 2000 | 474.8 Thousand CAD | 1452.61% |
| 1999 | 30.58 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.98 Million CAD | -15.48% |
| 2024 Q2 | 9.75 Million CAD | -2.28% |
| 2024 Q3 | 7.15 Million CAD | -26.67% |
| 2023 Q4 | 11.81 Million CAD | 14.97% |
| 2023 Q3 | 10.27 Million CAD | 4.75% |
| 2023 Q2 | 9.8 Million CAD | 17.42% |
| 2023 Q1 | 8.35 Million CAD | -1.17% |
| 2023 FY | 40.68 Million CAD | 64.36% |
| 2022 Q2 | 4.93 Million CAD | -4.68% |
| 2022 FY | 24.75 Million CAD | 256.86% |
| 2022 Q3 | 5.91 Million CAD | 19.8% |
| 2022 Q4 | 8.45 Million CAD | 42.99% |
| 2022 Q1 | 5.17 Million CAD | 110.59% |
| 2021 Q1 | 1.16 Million CAD | 19.58% |
| 2021 Q4 | 2.45 Million CAD | 50.16% |
| 2021 Q3 | 1.63 Million CAD | -2.36% |
| 2021 FY | 6.93 Million CAD | 31.88% |
| 2021 Q2 | 1.67 Million CAD | 43.82% |
| 2020 Q1 | 1.37 Million CAD | -23.59% |
| 2020 Q3 | 1.18 Million CAD | -31.28% |
| 2020 Q4 | 974.75 Thousand CAD | -17.84% |
| 2020 FY | 5.25 Million CAD | 31.23% |
| 2020 Q2 | 1.72 Million CAD | 25.84% |
| 2019 Q1 | 720.87 Thousand CAD | -13.74% |
| 2019 FY | 4 Million CAD | 8.14% |
| 2019 Q3 | 877.3 Thousand CAD | 42.81% |
| 2019 Q4 | 1.79 Million CAD | 104.68% |
| 2019 Q2 | 614.31 Thousand CAD | -14.78% |
| 2018 FY | 3.7 Million CAD | 40.21% |
| 2018 Q3 | 1.11 Million CAD | 12.42% |
| 2018 Q4 | 835.66 Thousand CAD | -24.86% |
| 2018 Q1 | 769.19 Thousand CAD | -22.56% |
| 2018 Q2 | 989.36 Thousand CAD | 28.62% |
| 2017 Q1 | 319.74 Thousand CAD | 66.56% |
| 2017 FY | 2.64 Million CAD | 5.67% |
| 2017 Q4 | 993.27 Thousand CAD | 51.55% |
| 2017 Q3 | 655.39 Thousand CAD | -2.9% |
| 2017 Q2 | 675 Thousand CAD | 111.11% |
| 2016 Q3 | 987.29 Thousand CAD | 51.12% |
| 2016 Q1 | 668.98 Thousand CAD | -24.99% |
| 2016 Q2 | 653.32 Thousand CAD | -2.34% |
| 2016 Q4 | 191.96 Thousand CAD | -80.56% |
| 2016 FY | 2.5 Million CAD | -13.31% |
| 2015 Q2 | 682.88 Thousand CAD | 6.93% |
| 2015 FY | 2.88 Million CAD | 3.3% |
| 2015 Q4 | 891.91 Thousand CAD | 32.68% |
| 2015 Q1 | 638.64 Thousand CAD | -7.07% |
| 2015 Q3 | 672.24 Thousand CAD | -1.56% |
| 2014 Q1 | 608.92 Thousand CAD | 9.75% |
| 2014 Q2 | 761.26 Thousand CAD | 25.02% |
| 2014 Q3 | 736.14 Thousand CAD | -3.3% |
| 2014 FY | 2.79 Million CAD | 35.27% |
| 2014 Q4 | 687.19 Thousand CAD | -6.65% |
| 2013 Q4 | 554.82 Thousand CAD | 39.66% |
| 2013 FY | 2.06 Million CAD | -20.67% |
| 2013 Q2 | 569.51 Thousand CAD | 4.78% |
| 2013 Q3 | 397.25 Thousand CAD | -30.25% |
| 2013 Q1 | 543.54 Thousand CAD | -41.7% |
| 2012 Q1 | 627.71 Thousand CAD | 25.92% |
| 2012 Q2 | 686.49 Thousand CAD | 9.36% |
| 2012 FY | 2.6 Million CAD | 12.17% |
| 2012 Q4 | 932.36 Thousand CAD | 58.36% |
| 2012 Q3 | 588.76 Thousand CAD | -14.24% |
| 2011 FY | 2.32 Million CAD | 25.82% |
| 2011 Q1 | 573.11 Thousand CAD | 16.56% |
| 2011 Q2 | 571.91 Thousand CAD | -0.21% |
| 2011 Q3 | 391.62 Thousand CAD | -31.52% |
| 2011 Q4 | 498.51 Thousand CAD | 27.29% |
| 2010 Q2 | 425.01 Thousand CAD | -5.19% |
| 2010 Q3 | 478.87 Thousand CAD | 12.67% |
| 2010 Q1 | 448.29 Thousand CAD | -1.28% |
| 2010 FY | 1.84 Million CAD | 24.09% |
| 2010 Q4 | 491.67 Thousand CAD | 2.67% |
| 2009 Q3 | 355.56 Thousand CAD | -8.7% |
| 2009 Q2 | 389.45 Thousand CAD | 33.76% |
| 2009 Q1 | 291.16 Thousand CAD | -53.13% |
| 2009 FY | 1.48 Million CAD | -47.54% |
| 2009 Q4 | 454.1 Thousand CAD | 27.71% |
| 2008 Q1 | 644.19 Thousand CAD | -37.45% |
| 2008 Q4 | 621.27 Thousand CAD | 25.31% |
| 2008 Q3 | 495.77 Thousand CAD | -54.98% |
| 2008 Q2 | 1.1 Million CAD | 70.96% |
| 2008 FY | 2.83 Million CAD | -23.77% |
| 2007 Q3 | 1.09 Million CAD | -4.69% |
| 2007 Q2 | 1.14 Million CAD | 153.09% |
| 2007 Q1 | 454.31 Thousand CAD | 1266.29% |
| 2007 Q4 | 1.02 Million CAD | -6.01% |
| 2007 FY | 3.71 Million CAD | 178.25% |
| 2006 Q3 | 142.87 Thousand CAD | -87.38% |
| 2006 Q2 | 1.13 Million CAD | 1028.35% |
| 2006 Q1 | 100.3 Thousand CAD | 6.71% |
| 2006 Q4 | -38.95 Thousand CAD | -127.27% |
| 2006 FY | 1.33 Million CAD | 210.01% |
| 2005 FY | 430.94 Thousand CAD | -34.46% |
| 2005 Q3 | 95.99 Thousand CAD | -39.68% |
| 2005 Q4 | 93.99 Thousand CAD | -2.08% |
| 2005 Q1 | 81.82 Thousand CAD | -35.36% |
| 2005 Q2 | 159.13 Thousand CAD | 94.48% |
| 2004 Q4 | 126.58 Thousand CAD | -29.99% |
| 2004 Q2 | 165.87 Thousand CAD | -9.96% |
| 2004 FY | 657.48 Thousand CAD | -21.97% |
| 2004 Q3 | 180.8 Thousand CAD | 9.0% |
| 2004 Q1 | 184.23 Thousand CAD | 53.98% |
| 2003 Q3 | 191.19 Thousand CAD | -23.53% |
| 2003 FY | 842.59 Thousand CAD | -44.31% |
| 2003 Q2 | 250.01 Thousand CAD | -11.26% |
| 2003 Q1 | 281.74 Thousand CAD | 15.29% |
| 2003 Q4 | 119.64 Thousand CAD | -37.42% |
| 2002 Q2 | 470.25 Thousand CAD | -0.05% |
| 2002 Q1 | 470.47 Thousand CAD | 0.0% |
| 2002 Q4 | 244.36 Thousand CAD | -25.49% |
| 2002 FY | 1.51 Million CAD | -31.88% |
| 2002 Q3 | 327.94 Thousand CAD | -30.26% |
| 2001 FY | 2.22 Million CAD | 367.82% |
| 2000 FY | 474.8 Thousand CAD | 1452.61% |
| 1999 FY | 30.58 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ContraFect Corporation | 56.88 Million USD | 28.483% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 53.12% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -727.283% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -15444.908% |
| SQZ Biotechnologies Company | 85.61 Million USD | 52.481% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1295.123% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -37.668% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -9.205% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2608.908% |
| Marizyme, Inc. | 19.23 Million USD | -111.463% |
| Genus plc | 147.7 Million USD | 72.454% |
| Pharming Group N.V. | 225.49 Million USD | 81.957% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1885.892% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2932.702% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -387.889% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2651.311% |
| IMV Inc. | 37.7 Million USD | -7.892% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1358.06% |
| ONE Bio Corp. | 6.44 Million USD | -531.374% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 52.662% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -10343.69% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1448.42% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3992.316% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 59.041% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -505.611% |
| Skye Bioscience, Inc. | 13.54 Million USD | -200.313% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2082.242% |
| Mesoblast Limited | 5.9 Million USD | -589.344% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 162840.264% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -706.916% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -154.119% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -2117.055% |
| GB Sciences, Inc. | 1.42 Million USD | -2764.119% |
| MultiCell Technologies, Inc. | 567.42 USD | -7170085.401% |
| Alpha Cognition Inc. | 9.7 Million USD | -319.192% |
| HST Global, Inc. | 140.9 Thousand USD | -28773.701% |
| CSL Limited | 3.44 Billion USD | 98.82% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 1.37 Million USD | -2865.911% |
| Halberd Corporation | 74.84 Thousand USD | -54261.276% |
| Enzolytics Inc. | 2.17 Million USD | -1766.71% |
| Resverlogix Corp. | 12.71 Million USD | -220.052% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1014.443% |
| argenx SE | 1.53 Billion USD | 97.347% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3797.037% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -64.617% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1094.87% |
| Bioxytran, Inc. | 3.82 Million USD | -965.013% |
| Zenith Capital Corp. | 8.94 Million USD | -354.938% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1557.019% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -23621.826% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -2018.014% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 825.34 Million USD | 95.071% |
| Kadimastem Ltd | 2.41 Million USD | -1588.099% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1963.102% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -2212.074% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -274.391% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -363.424% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -822.842% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -985.972% |
| EV Biologics, Inc. | 531.96 Thousand USD | -7548.115% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -22317.867% |
| Q BioMed Inc. | 3.43 Million USD | -1083.866% |
| LadRx Corporation | 3.81 Million USD | -967.348% |
| Cell Source, Inc. | 4.32 Million USD | -840.62% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -9692.328% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4305.482% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 29.169% |
| Itoco Inc. | 919.14 Thousand USD | -4326.413% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -859.913% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -3516.74% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1591.733% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -3535.841% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2476.056% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -456.547% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -233440.359% |
| NovAccess Global Inc. | 2.46 Million USD | -1549.331% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -161547.527% |
| BioStem Technologies, Inc. | 22.97 Million USD | -77.086% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -18386.657% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2946.587% |
| Qrons Inc. | 643.67 Thousand USD | -6220.727% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2765.565% |
| SYBLEU INC | 160.87 Thousand USD | -25189.705% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1724.541% |
| Rebus Holdings, Inc. | 664 Thousand USD | -6027.269% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4305.482% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -2139.972% |
| Affymax, Inc. | 39.38 Million USD | -3.298% |
| Mobile Lads Corp. | 554.54 Thousand USD | -7236.644% |
| International Stem Cell Corporation | 5.27 Million USD | -671.866% |
| CytoDyn Inc. | 18.05 Million USD | -125.302% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -77186.323% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -199895.409% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -12.185% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -2414.528% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -5429.102% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1207.781% |
| Neutra Corp. | 243.82 Thousand USD | -16586.449% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -133.059% |
| PureTech Health plc | 144.59 Million USD | 71.863% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -98.562% |
| IXICO plc | 4.7 Million USD | -764.352% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -362.488% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 65.447% |
| CSL Limited | 3.89 Billion USD | 98.955% |
| Cellectis S.A. | 97.32 Million USD | 58.195% |